WEBULL
News
AVDL
21.34
-0.07%
-0.02
Alkermes To Acquire Avadel Pharmaceuticals In Shareholder Scheme, Sends Proposal To Equity And Employee Share Purchase Plan Holders
Benzinga · 19h ago
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
Barchart · 3d ago
AVADEL PHARMACEUTICALS PLC - SCHEME MEETING AND EGM SCHEDULED FOR JANUARY 12, 2026
Reuters · 4d ago
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
Barchart · 5d ago
Weekly Report: what happened at AVDL last week (1124-1128)?
Weekly Report · 5d ago
Hold Rating on Avadel Pharmaceuticals Amid Acquisition Offer and Market Uncertainties
TipRanks · 11/26 21:15
Jefferies expects Avadel-Alkermes deal to close
TipRanks · 11/26 21:05
Weekly Report: what happened at AVDL last week (1117-1121)?
Weekly Report · 11/24 09:50
Avadel Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 11/20 15:52
Wells Fargo Maintains Equal-Weight on Avadel Pharmaceuticals, Raises Price Target to $22.5
Benzinga · 11/20 15:42
Avadel Pharmaceuticals (AVDL) Gets a Hold from Wells Fargo
TipRanks · 11/20 13:56
Avadel Pharmaceuticals price target raised to $22.50 from $20 at Wells Fargo
TipRanks · 11/20 11:40
BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
Reuters · 11/19 18:59
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)
TipRanks · 11/19 15:30
BRIEF-H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options
Reuters · 11/19 14:23
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid
Seeking Alpha · 11/19 12:00
Avadel Pharmaceuticals Amends Agreement with Alkermes
TipRanks · 11/19 11:48
Alkermes Raises Offer To Acquire Avadel In Deal Worth Up To $22.50 Per Share
NASDAQ · 11/19 11:38
Avadel Pharmaceuticals (AVDL) Receives a Hold from H.C. Wainwright
TipRanks · 11/19 11:36
Alkermes increases offer to acquire Avadel Pharmaceuticals to $22.50 per share
TipRanks · 11/19 11:15
More
Webull provides a variety of real-time AVDL stock news. You can receive the latest news about Avadel Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.